Close
SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMC NEWS

TMCNET eNEWSLETTER SIGNUP

GSK forms partnership with Vodafone to help increase childhood vaccination in Mozambique; Partnership aims to create sustainable and scalable model to be replicated across Africa
[December 10, 2012]

GSK forms partnership with Vodafone to help increase childhood vaccination in Mozambique; Partnership aims to create sustainable and scalable model to be replicated across Africa

(M2 PressWIRE Via Acquire Media NewsEdge) GSK today announced it has formed a partnership with Vodafone to harness innovative mobile technology to help vaccinate more children against common infectious diseases in Africa. Despite major advances in the funding and availability of vaccines worldwide, it is estimated that up to a fifth of children worldwide still do not receive basic vaccines. The proliferation of mobile phones in Africa offers an opportunity to create innovative and cost-effective ways to address barriers to universal vaccination.

The initial focus of the new partnership will be a one-year pilot vaccination project in Mozambique, supported by Save the Children and run in collaboration with the Mozambique Ministry of Health. This project aims to establish if mobile technology solutions could increase the proportion of children covered by vaccination in Mozambique by an additional 5-10% through helping to encourage mothers to take up vaccination services, support health workers, improve record keeping, and enable better management of vaccine stock.

If successful, the project will create a model that can be replicated throughout Mozambique and then scaled across Africa to reach thousands more children with life-saving vaccination.


Sir Andrew Witty, CEO of GSK, said: "Innovative technologies -- whether mobile devices, medicines or vaccines -- are helping to transform global health. Organisations such as UNICEF and GAVI have played a key role in making vaccines much more accessible in Africa but barriers still exist which stop children from benefitting from basic immunisation. This new partnership combines GSK's expertise, knowledge and resources with those of Vodafone with the potential to deliver life-saving vaccines to tens of thousands more children in Mozambique. Our hope is that together we will create a sustainable and scalable model which could ultimately be replicated to help more children live healthy lives across developing countries." Vittorio Colao, CEO of Vodafone, said: "Vodafone is committed to investing in mobile technologies that can transform healthcare in both developed and emerging markets. These partnerships have the potential to save millions of children's lives in some of the world's poorest countries and we are delighted to support this critically important endeavour." The pilot will use mobile technology to address barriers to increased take-up of vaccines in Mozambique in three key ways: Mothers and caregivers will be registered on a Mozambique Ministry of Health database and alerted by SMS to the availability and importance of lifesaving vaccinations against common childhood diseases. Mothers will be able to schedule vaccination appointments by SMS and receive notifications of past and future vaccinations to ensure children complete the full schedule and become fully immunised. Health workers will be provided with smartphones with software allowing them to contact mothers, view and record vaccination histories, schedule vaccinations and report on follow-up visits. Healthcare facilities will be prompted to regularly report on crucial vaccination stock levels by SMS. This will enable critical supply chain management and the availability of vaccines when and where they are needed, particularly in rural areas.

The pilot will include up to 100 clinics and will be independently tested to prove its impact, effectiveness and cost benefits. To ensure open access, the platform will be available to caregivers across any mobile network and can be used to increase take-up of any selected vaccine.

GSK is a global healthcare company with a long history in the developing world. Its vaccines are included in immunisation campaigns in 173 countries worldwide and of the 1.1 billion vaccine doses delivered in 2011, 870 million doses (more than 80%), were shipped for use in developing countries.

In 2010, GSK created the dedicated Developing Countries and Market Access operating unit which is focused on expanding access to medicines for people in the world's poorest countries. In least developed countries, GSK focuses on increasing the volume of medicines supplied rather than revenue generated. It caps the prices of GSK patented medicines and vaccines at no more than 25% of developed world prices and reinvests 20% of profits back into projects that strengthen healthcare infrastructure in these countries.

Vodafone is one of the world's largest mobile communications companies. It has experience of developing commercial mobile health solutions in other African countries: 5,000 clinics across Tanzania currently use Vodafone's mobile stock management service to track malaria treatments and more than 1,800 remote community healthcare workers in South Africa are using a mobile solution to access and update patient records.

Today's announcement adds to GSK initiatives aimed at using mobile technology to improve healthcare in Africa: Since 2011, GSK has been involved in an initiative using mobile technology to help tackle the issue of counterfeit medicines in Africa where 10-30% of all medicines sold are thought to be counterfeit. In collaboration with the National Agency for Food and Drug Administration Control (NAFDAC) in Nigeria, GSK introduced packs of antibiotics which contain a scratch-off panel that reveals a unique code which can sent by text message to verify a product as genuine. Following this successful pilot, NAFDAC has now mandated that a similar technology be applied to all antibiotics and anti-malarials in Nigeria from next year. GSK is introducing similar programmes in Kenya and Tanzania, with the hope to scale up across East Africa. In Rwanda, GSK has formed a partnership with the private enterprise One Family Health (OFH) Foundation, Ecobank and the Rwandan Ministry of Health to establish up to 250 health posts across Rwanda over the next three years. Funded through low-interest loans, community nurses set up their own clinics in areas of low healthcare infrastructure to deliver essential medicines and basic healthcare in remote locations. Nurses are provided with internet-enabled mobile phones allowing them to access patient records and monitor stocks of medicines in real-time. This innovative approach not only increases access to healthcare but also provides a sustainable income for the healthcare workers involved.

GlaxoSmithKline -- one of the world's leading research-based pharmaceutical and healthcare companies -- is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com .

GlaxoSmithKline Enquiries: UK Media enquiries: David Mawdsley +44 (0) 20 8047 5502 (London) Sarah Spencer +44 (0) 20 8047 5502 (London) David Daley +44 (0) 20 8047 5502 (London) Catherine Hartley +44 (0) 20 8047 5502 (London) Alex Harrison +44 (0) 20 8047 5502 (London) US Media enquiries: Stephen Rea +1 215 751 4394 (Philadelphia) Kevin Colgan +1 919 483 2933 (North Carolina) Melinda Stubbee +1 919 483 2510 (North Carolina) Mary Rhyne +1 919 483 0492 (North Carolina) Sarah Alspach +1 202 715 1048 (Washington, DC) Jennifer Armstrong +1 215 751 5664 (Philadelphia) Analyst/Investor enquiries: Sally Ferguson +44 (0) 20 8047 5543 (London) Lucy Budd +44 (0) 20 8047 2248 (London) Tom Curry + 1 215 751 5419 (Philadelphia) Gary Davies + 44 (0) 20 8047 5503 (London) James Dodwell + 44 (0) 20 8047 2406 (London) Jeff McLaughlin + 1 215 751 7002 (Philadelphia) Ziba Shamsi + 44 (0) 20 8047 3289 (London) Cautionary statement regarding forward-looking statements Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under 'Risk factors' in the 'Financial review & risk' section in the company's Annual Report 2011 included as exhibit 15.2 to the company's Annual Report on Form 20-F for 2011.

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com)).

(c) 2012 M2 COMMUNICATIONS

[ Back To TMCnet.com's Homepage ]





LATEST VIDEOS

DOWNLOAD CENTER

UPCOMING WEBINARS

MOST POPULAR STORIES





Technology Marketing Corporation

800 Connecticut Ave, 1st Floor East, Norwalk, CT 06854 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2014 Technology Marketing Corporation. All rights reserved.